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BACKGROUND: New screening technologies and vaccination against human papillomavirus (HPV), the necessary cause of cervical
cancer, may impact optimal approaches to prevent cervical cancer. We evaluated the cost-effectiveness of alternative screening
strategies to inform cervical cancer prevention guidelines in Norway.
METHODS: We leveraged the primary epidemiologic and economic data from Norway to contextualise a simulation model of HPV-
induced cervical cancer. The current cytology-only screening was compared with strategies involving cytology at younger ages and
primary HPV-based screening at older ages (31/34þ years), an option being actively deliberated by the Norwegian government.
We varied the switch-age, screening interval, and triage strategies for women with HPV-positive results. Uncertainty was evaluated in
sensitivity analysis.
RESULTS: Current cytology-only screening was less effective and more costly than strategies that involve switching to primary HPV
testing in older ages. For unvaccinated women, switching at age 34 years to primary HPV testing every 4 years was optimal given
the Norwegian cost-effectiveness threshold ($83000 per year of life saved). For vaccinated women, a 6-year screening interval was
cost-effective. When we considered a wider range of strategies, we found that an earlier switch to HPV testing (at age 31 years)
may be preferred.
CONCLUSIONS: Strategies involving a switch to HPV testing for primary screening in older women is expected to be cost-effective
compared with current recommendations in Norway.
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Cytology-based screening programmes that have achieved com-
prehensive coverage have been credited with significant reductions
in incidence of and mortality from invasive cervical cancer
through early detection and treatment (Hakama and Hristova,
1997; Peto et al, 2004; Bray et al, 2005). Despite successful
screening, cervical cancer is still among the three most frequent
cancers for women 25–49 years of age in Norway, where incidence
and mortality rates are 9.5 and 1.7 per 100000 women-years,
respectively (Cancer Registry of Norway, 2011). Since 1995, the
Norwegian Coordinated Cervical Cancer Screening Program has
invited women to cytology-based screening every 3 years. Recent
clinical studies have reported that human papillomavirus (HPV)
DNA testing has a higher sensitivity for detecting high-grade
precancerous lesions (Arbyn et al, 2006), possibly resulting in
more opportunities for early detection and treatment. In addition,
data combined from six European countries suggests that the
primary screening interval may be safely extended by using HPV
DNA testing (Dillner et al, 2008).
In the autumn of 2009, vaccination against HPV was introduced
as part of the childhood immunisation programme for preadoles-
cent girls, free of charge. The HPV vaccine protects against two
carcinogenic HPV types, 16 and 18, that cause B70% of cervical
cancers in Norway, as well as two non-carcinogenic types, 6 and
11, that cause the majority of genital warts. HPV vaccination of
older women has not been implemented, and screening will
continue to remain the main source of prevention against cervical
cancer for the current population of Norwegian women who are
past the vaccination target age, as well as those who do not receive
the vaccine in adolescence. Importantly, screening will also
continue to be critical among those vaccinated to prevent the
30% of cancer cases that are not attributable to the vaccine types.
Given the availability of HPV vaccines and highly sensitive HPV
DNA tests (Franco, 2003; Arbyn et al, 2006; Cuzick et al, 2006a,b),
countries around the world are evaluating new screening
algorithms that use HPV DNA testing for primary screening;
however, determining the optimal approach to cervical cancer
prevention is quite complex and involves multiple tradeoffs. For
example, despite the higher sensitivity of the HPV DNA test for
high-grade cervical intraepithelial neoplasia (CIN), health officials
have concerns with regard to the low clinical specificity of the test,
which may result in over referrals (i.e., excess burden for women
and health services). This limitation may be minimised by an
algorithm that relies more heavily on identifying HPV persistence
rather than immediately subjecting women directly to colposcopy/
biopsy, a diagnostic procedure that may be associated with
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decision-analytic methods to synthesise and extrapolate clinical,
epidemiological, and economic evidence beyond the capacity of
empirical trials, may aid decisions regarding the optimal
secondary prevention strategies under various scenarios of
uncertainty (Goldie, 2003). Such models can estimate the lifetime
risk of dying from cervical cancer, life expectancy, and lifetime
costs related to screening and treatment of cervical cancer. These
data are then used to estimate the additional costs and life years
saved of a particular screening strategy, compared the current
recommended strategy. In Norway, the health benefit of an
intervention or strategy is considered to be good value for money
if the additional life year costs o500000 Norwegian Kroner (NOK;
E$83000). In this study, we use a decision-analytic model to
assess the impact of adopting recently proposed cervical cancer
prevention strategies involving primary HPV DNA testing
(Cancer Registry of Norway, 2011) in order to inform policy
recommendations in Norway. Specifically, our analysis addresses
whether women who have been vaccinated against HPV can be
screened efficiently using primary HPV DNA testing and whether
the optimal strategy may differ for those women who have not
been vaccinated.
MATERIALS AND METHODS
Analytic approach
We adapted an existing mathematical model to reflect the natural
history of HPV-induced cervical cancer in Norway (Goldhaber-
Fiebert et al, 2007; Kim et al, 2007; Kim and Goldie, 2008). The
model was adjusted to the Norwegian context using primary
clinical and cost data from Norway to project the health and
economic outcomes associated with different scenarios of screen-
ing. We compared the currently recommended cytology-based
programme with alternative screening strategies that use HPV
DNA testing for women who have been either vaccinated or not
vaccinated against HPV-16 and HPV-18 in pre-adolescence.
Outcomes included lifetime risk of cancer, life expectancy, and
lifetime costs. Incremental cost-effectiveness ratios (ICERs),
calculated as the additional dollar ($) for each additional year of
life saved (YLS) of a strategy compared with the next most costly
strategy, was used as a performance indicator. Strategies that were
more costly and less effective (dominated) or less costly and less
cost-effective (weakly dominated) were removed from the cost-
effectiveness calculations. The ‘most cost-effective’ intervention is
not necessarily the one that has the lowest ratio as society may be
willing to pay more for health benefit. We used the proposed
willingness-to-pay threshold of 500000 NOK (E$83000) per YLS
to signify the amount below which an intervention would be
considered ‘good value for money’ (Norwegian Directorate of
Health, 2007). We adopted a societal prospective, including all
costs and benefits regardless to whom they accrue, and discounted
costs and benefits by 4% per year, as recommended in Norway
(Norwegian Finance Department, 2005). Uncertain parameters and
scenarios were explored extensively in sensitivity analysis.
Model overview
The individual-based stochastic model has been previously
described (Goldhaber-Fiebert et al, 2007; Kim et al, 2007; Kim
and Goldie, 2008). The model simulates the natural history of
HPV-induced cervical cancer in a series of mutually exclusive,
collectively exhaustive health states. A cohort of females enters the
model and can transition between health states in monthly
intervals until death. Transition probabilities are a function of
HPV type, history of prior HPV infection (i.e., natural immunity),
and age. The model is static in that HPV incidence changes as a
function of age, but does not change as a function of sexual activity
or HPV prevalence in the population over time. Indirect effects of
vaccination on risk of HPV infection (i.e., herd immunity) were
explored in a sensitivity analysis by reducing HPV incidence in
unvaccinated women. Health states were stratified according to
HPV infection (no infection, high-risk type 16, high-risk type 18,
other high-risk types and low-risk types (Munoz et al, 2003)),
CIN grade 1 (CIN1), CIN grade 2, 3 (CIN23), invasive cancer
(local, regional or distant), and death. Women with cancer can be
identified either through screening or from symptoms, or they may
remain undetected and progress to more advanced stages of
cancer. Women with cancer face stage-specific survival rates; all
women face competing mortality risks from other causes based on
Norway life tables (Statistics Norway, 2011).
Epidemiologic data
Baseline transition parameter values describing the natural history
of disease were based on the best available empirical data and
assume that the underlying mechanism of cervical carcinogenesis
does not vary across epidemiological settings. However, risk
factors, such as sexual behaviour, and cervical cancer incidence
rates differ between countries; therefore, country-specific data are
needed to adjust baseline inputs to account for variations in
progression and regression rates. We leveraged empirical data
from Norway and used a likelihood-based algorithm to identify
candidate sets of parameter values that achieve good-fit to
epidemiological outcomes observed in the Norwegian population.
Specifically, Norwegian data used for calibration included age-
specific prevalence of HPV-16, HPV-18 (Mari Nygaard, personal
communication) and of CIN23 in Norwegian women (Molden et al,
2005, 2006); the relative contributions of HPV-16, HPV-18 and
other high-risk HPV types in CIN23 and cervical cancer (Steinar
Thoresen, personal communication), and pre-screening (1953–
1969) cancer incidence rates were obtained from the Cancer
Registry of Norway. The parameterisation and likelihood-based
calibration process have been described previously (Goldhaber-
Fiebert et al, 2007; Kim et al, 2007; Kim and Goldie, 2008); details
of the Norwegian-specific calibration for the current analysis
are included in the Supplementary Appendix. All analyses were
conducted with 50 statistically indistinguishable (i.e., good-fitting)
parameter sets to incorporate the effect of uncertainty surrounding
the natural history of cervical cancer. Results were reported as the
mean of outcomes across the 50 parameter sets, and ICERs were
calculated as the incremental mean costs divided by the
incremental mean effects of two strategies (Stinnett and Paltiel,
1997). Screening test characteristics (i.e., sensitivity and specifi-
city) were based on published studies and varied in sensitivity
analyses (Franco, 2003; Sherman, 2003; Solomon, 2003; Arbyn
et al, 2006; Cuzick et al, 2006a,b).
Cost data
Direct medical and non-medical costs associated with screening,
vaccination, and treatment were estimated using a combination of
official Norwegian guidelines (Norwegian Medical Association,
2010a) and expert opinion. All costs were measured in 2010 NOK
and converted to US dollars (US $) using the average annual 2010
exchange rate (US $1¼NOK6.05) (Federal Reserve, 2011). Direct
medical costs for screening, diagnosis, and treatment of dysplasia
and invasive cervical cancer were based on Norwegian Diagnosis
Related Groups (DRGs) and the Fee Schedules for General
Practitioners and Specialists (Norwegian Directorate of Health,
2010; Norwegian Medical Association, 2010b,c; Table 1). Screening
laboratory costs were adjusted to reflect potential discrepancies
between published reimbursement rates and true economic costs
(additional details in the Supplementary Appendix). We based
HPV vaccination costs on a published report from the Norwegian
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tered over the course of 6 months (Norwegian Medicines Agency,
2010).
Direct non-medical costs were estimated to account for the
production loss and the transportation costs associated with
screening and treatment. We used the average 2010 gross monthly
income of Norwegian women obtained from Statistics Norway
(2011) and adjusted the wage to include social benefits paid by
employers. Travel time and transportation costs associated with
screening and follow-up visits were estimated from a prospective
study of colorectal screening in Norway (Aas, 2009). The time
spent travelling to a hospital to receive cervical cancer treatment
was estimated from a health survey conducted by the Statistics
Norway for the World Health Organization (2003). We attributed
zero production loss or transportation costs for the children or
their parents to receive the HPV vaccination, as it is given as part
of the school administered vaccination programme for girls in the
7th grade. Additional details and costing assumptions can be
found in the Supplementary Appendix. The costs of cancer
treatment, CIN treatment, screening test, colposcopy, and office
visits were varied widely (50 and 200% of base case values) in one-
way sensitivity analyses.
Strategies
The current Norwegian screening strategy involves triennial
cytologic evaluation of cervical cells (i.e., cytology) followed by
repeat cytology in combination with HPV testing for atypical
squamous cells of undetermined significance or low-grade
squamous intraepithelial lesion (LSIL) 6 months later (herein
referred to as ‘cytology-based screening’). Women with high-grade
squamous intraepithelial lesions are referred directly to colpo-
scopy/biopsy. The proposed strategy involves switching older
women (age X34 years) from the current strategy to primary HPV
DNA testing with liquid-based cytology (LBC) triage for women
found to be positive for hrHPV types (herein referred to as ‘HPV
with reflex LBC’). For women who are HPV-positive and cytology-
negative (HPVþ/Cyt ), the strategy uses a period of intensified
screening to identify women who are persistently HPVþ/Cyt ,
requiring three additional HPVþ/Cyt  results each with 12
months apart before receiving a referral for colposcopy/biopsy.
Our primary analysis included 24 variations of the strategy
specified by the Norwegian proposal and immediately relevant for
Norwegian policy decisions (Figure 1). We compared variations of
the strategy that differed by routine screening interval, the number
of persistent HPVþ/Cyt  results, and the month interval between
repeat testing required prompting colposcopy. We then conducted
a secondary analysis, which included the same strategies but
allowed the age at which women switch from cytology to primary
HPV testing (i.e., 31 or 34 years) to vary. In addition, we allowed
younger women with LSIL to be referred directly to colposcopy, as
recommended in other settings (Wright et al, 2007). The secondary
analysis also included a strategy of pre-adolescent vaccination only
without screening. For all analyses, we held the screening start and
stop ages constant and maintained the 3-year screening interval for
younger women (pre-switch). We evaluated the optimal strategies
for two sub-groups of women: those who had been vaccinated and
those who had not been vaccinated in pre-adolescence.
Screening compliance was assumed to be 100% to allow
comparison of the maximum benefit for each strategy; however,
this assumption was varied in sensitivity analysis. For this
variation, we assumed that the risk is equally distributed across
attenders and non-attenders and there was no change in future
screening behaviour. For strategies that incorporate vaccination,
we assumed that: (1) the vaccination is given to sexually naive girls
at the age of 12 years; (2) all girls receive the recommended three
doses of the vaccine; (3) vaccination is 100% effective in
preventing HPV-16, HPV-18, but does not give any protection
against contracting other high-risk HPV types (i.e., no cross-
protection); and (4) duration of vaccine immunity is lifelong (see
Supplementary Appendix for additional assumptions).
In addition to varying costs, we varied the test characteristics of
cervical cytology and evaluated the impact of uncertainty around
herd immunity, vaccine efficacy, and waning vaccine protection in
sensitivity analyses. To explore the impact of screening coverage,
we applied a distribution of screening frequencies across the
cohort. For this we assumed 15% were non-screeners, 70%
complied with the specified interval, and the remaining 15% were
screened less frequently (1 year delay each screening round).
Although simplified, these assumptions are consistent with
estimates documented by the Norwegian Cancer Registry (Cancer
Registry of Norway, 2009). Last, we conducted a probabilistic
sensitivity analysis by using the 50 good-fitting parameter sets.
RESULTS
Analysis including currently proposed Norwegian
strategies only
In the primary analysis and regardless of vaccination status, the
current cytology-based screening strategy was less effective and
Table 1 Selected model inputs
Cost
Value
($)
Range
($)
Screening
Conventional cytology 49 8
a
Liquid-based cytology 50 12
a
HPV DNA testing
b 62 54
a
Office visit, patient time, and transport 160 80–321
Colposcopy with biopsy
c 337 168–674
CIN treatment
c
CIN1 1024 512–2047
CIN2/3 2162 1081–4325
Cancer treatment
c
Local 25770 12885–51539
Regional 51589 25795–103179
Distant 59635 29818–119270
Vaccine
Per dose 163
Test characteristics
Value
(%)
Range
(%)
HPV DNA performance for detection of CIN
d
Probability of HR-HPV given HR-HPV 100
Probability of no HR-HPV given no HR-HPV 100
Cytology performance for detection of CIN
e
Probability of abnormal cytology given CIN1 70 40–70
Probability of abnormal cytology given CIN2/3+ 80 40–80
Probability of normal cytology given
normal histology
95
Abbreviations: HPV¼human papillomavirus; CIN¼cervical intraepithelial neoplasia.
aBased on published reimbursement fees.
bShares co-collection fee with liquid-based
cytology.
cIncludes office costs, patient time, and transport.
dProbability of HR-HPV
DNA positivity given high-risk HPV is assumed to be 100%; output from the model
indicates the clinical sensitivity of HPV DNA testing for detecting CIN2 or worse is
B80% (min: 62%; max: 95%). Specificity for CIN2 and worse is B89% (min: 85%;
max: 94%).
eAbnormal cytology is defined as atypical squamous cells of undetermined
significance or worse. Local: stage Ia–IIa; Regional: stage IIb–IIIb; Distant: IVa–IVb.
All costs are expressed in 2010 US dollars (US$¼NOK6.05).
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that involve switching to primary HPV testing at 34 years of age.
For unvaccinated women, the optimal (cost-effective) strategy
involves switching at age 34 years to primary HPV DNA testing
with a 4-year screening interval. For women HPVþ/Cyt , optimal
management involves three additional persistent HPVþ/Cyt 
results 6 months apart, before colposcopy referral. This strategy is
associated with a cost-effectiveness ratio of $83000 per YLS,
compared with the next best strategy and yields an expected
reduction in lifetime cervical cancer risk of 65%, compared with no
screening (Figure 2A). By comparison, the current cytology-based
screening programme gives an expected cancer risk reduction
of B55%.
For vaccinated women, the preferred screening strategy involves
extension of the screening interval to every 6 years after the switch-
age of 34 years with the same follow-up of HPVþ/Cyt  women as
for unvaccinated women. This strategy had a cost per YLS of
$76000, compared with the next best strategy and an expected
cancer risk reduction of 85.7% (Figure 2B); nearly the same
expected reduction as screening women every 3 years with the
current strategy, but for a lower lifetime cost. If vaccinated women
followed the same strategy that is optimal for unvaccinated women
(i.e., screening every 4 years after age 34 years), the ICER would be
well over what is considered good value for the cost. On the other
hand, if older, unvaccinated women were screened every 6 years
(as recommended for vaccinated women), rather than every 4
years, they would be forgoing an additional 8% absolute reduction
in cancer, compared with no intervention.
Analysis including additional strategies
Switching unvaccinated women to primary HPV DNA testing at
age 31 years was always preferred over strategies that involved
switching at the proposed age of 34 years. Switching at a younger
age provided equal or greater reductions in cervical cancer and
could cost up to 24% less over a woman’s lifetime compared with
the current screening strategy (Table 2). The optimal strategy, with
an ICER of $76000 per YLS, entails switching at age 31 years to
primary HPV DNA testing every 4 years with reflex LBC (Table 2;
top panel). This strategy requires women who are HPVþ/Cyt  to
have three persistent results 12 months apart, before colposcopy
referral. This strategy, compared with the optimal strategy, identified
by our primary analysis has similar benefits, but would be expected
to cost B5% less per woman over her lifetime. Variants of this
screening strategy were less attractive. If a 3-year screening interval
was maintained for older women using HPV DNA testing and the
most intensive follow-up of HPVþ/Cyt  women, we estimated that
it provides nominal life expectancy gains at a cost of approximately
$513000 per YLS, compared with the next best strategy.
For women vaccinated during adolescence, switching at an
earlier age to HPV DNA testing may also provide similar benefit at
a lower cost per woman compared with switching at age 34 years.
The optimal strategy involved a 6-year screening interval after the
switch-age of 31 years and requires two additional HPVþ/Cyt 
results 12 months apart, before colposcopy referral (Table 2;
bottom panel). Compared with switching women to 6-yearly HPV
screening at age 34 years and the current cytology-based pro-
gramme, vaccinated women may achieve similar cancer risk
reductions by switching at the earlier age but could reduce the
cost per woman over her lifetime by an additional 5% and 18%,
respectively.
Sensitivity analysis
Overall results were not sensitive to cancer and CIN treatment
costs or the imperfect screening compliance scenarios. Results
HPV+/Cyt–
1st Repeat visit
New HPV test
6 or 12
Months
6 or 12
Months
6 or 12
Months
HPV+/Cyt+
Colpo/biopsy
CIN2+ CIN2+
New HPV
index test
Treat Treat Varied in the model
Colpo/biopsy Normal/
CIN1
Reflex
cytology
HPV+
HPV index test
(Age 31, 34)
(B)
(C)
HPV test (3,4, 5, or 6 years)
HPV–
(A)
2nd Repeat visit 3rd Repeat visit
Screening Screening Screening
hrHPV–
hrHPV+/Cyt–
hrHPV+/Cyt+
New HPV test New HPV test
New HPV
index test
New HPV
index test
CIN2+
Treat
CIN2+
Treat
Normal/
CIN1
Colpo/biopsy Colpo/biopsy Normal/
CIN1
hrHPV–
hrHPV+/Cyt–
hrHPV+/Cyt+
hrHPV+/Cyt–
hrHPV+/Cyt+
hrHPV–
Figure 1 Flow diagram for proposed HPV DNA screening strategy. The strategy involves switching older women (age X31 or 34 years) from cytology-
based screening to primary HPV DNA testing with LBC triage for women found to be positive for hrHPV types; women with abnormal cytology are then
referred directly to colposcopy with biopsy. We compared variations of the strategy, which differed by screening interval (3–6 years), the number of
persistent HPVþ/Cyt  results (e.g., 1, 2, or 3 persistent result(s)), and the month interval between repeat testing (e.g., 6- or 12-month follow-up intervals)
required to prompt colposcopy. In the base case, the switch age of screening was 34 years; in a secondary analysis, we allowed women to switch at an earlier
age (31 years). Abbreviations: CIN¼cervical intraepithelial neoplasia; Colpo/biopsy¼colposcopy with biopsy; hrHPV¼high-risk human papillomavirus;
HPVþ/Cyt ¼HPV-positive and cytology-negative result; LBC¼liquid-based cytology.
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and vaccine efficacy. For example, if the cost of a colposcopy/
biopsy doubled ($674 rather than the $337 assumed in the base
case), the optimal primary screening interval for vaccinated
women remained constant, but the follow-up strategy requires
three persistent HPVþ/Cyt  results rather than two persistent
HPVþ/Cyt  results to prompt referral for colposcopy. Results
were most sensitive to cytology test characteristics, inclusion of
herd immunity benefits, and office-visit costs. When we explored
the potential decrease in the sensitivity of cytology after the
introduction of vaccination, the most cost-effective strategy for
vaccinated women require fewer persistent HPVþ/Cyt  results
before verification using colposcopy/biopsy. Simulating the
indirect protection unvaccinated women receive from vaccinated
women allowed for extension of the recommended screening
interval by 1 year (i.e., every 5 years rather than every 4 years for
women 31 years and older). If office-visit costs doubled (including
the transport and time costs of women), it was optimal to refer
women to colposcopy/biopsy after only one persistent HPVþ/
Cyt  result rather than requiring three persistent results.
Additional sensitivity analysis results are included in the
Supplementary Appendix.
We used the 50 good-fitting natural history parameter sets to
estimate the probability that the optimal strategies in the primary
analysis are cost-effective according the Norwegian cost-effective-
ness threshold. For unvaccinated women 34 years or older,
switching to primary HPV DNA testing with a 4-year screening
interval was found optimal in the majority of the simulations
(58%), whereas a 6-year screening interval was never preferred.
The analogous results for vaccinated women indicated that a 6-
year screening interval was optimal in 94% of the simulations and
a 5-year screening interval was optimal in 6% of the simulations.
DISCUSSION
With the advent of new HPV diagnostics, secondary preventative
strategies have the potential to further reduce the burden of
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Figure 2 Efficiency frontiers showing the trade-off of costs and benefits. Discounted life expectancy, lifetime costs, reduction in lifetime risk of cancer, and
ICERs for alternate cervical cancer screening strategies for women 34 years and older from the ‘primary analysis’ (see the Results for details) for either
unvaccinated (A) or vaccinated (B) women. Strategies lying on the efficiency curve are either less costly and more effective (i.e., strongly dominant) or more
costly but more cost-effective (i.e., weakly dominant) than those lying to the right of the curve. The slope of the efficiency curve (also the inverse of the
ICER) will be steeper when the net gain in the life expectancy per dollar is greater. Abbreviations: HPV¼human papillomavirus; HPVþ/Cyt ¼HPV-
positive and cytology-negative result; ICER¼incremental cost-effectiveness ratio; LBC¼liquid-based cytology.
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vaccination, two distinct risk groups will emerge as cohorts of
vaccinated girls become eligible for screening. Model-based
analyses can assist decision-makers faced with choosing new
screening technologies that have the potential to be more
beneficial than current strategies. Consistent with another analysis
(Goldhaber-Fiebert et al, 2008), we found that HPV DNA testing in
older women can be more cost-effective than cytology-only based
strategies, for both vaccinated and unvaccinated women. For
women who are not vaccinated, our primary analysis projected
that the optimal strategy for primary screening involves cytology
for younger women and HPV DNA testing with reflex LBC every 4
years for women aged 34 years and older. The algorithm requires
three additional persistent HPVþ/Cyt  results 6 months apart,
before colposcopy referral. For vaccinated women, the primary
screening interval for older women could be extended to 6 years
with the same follow-up for HPVþ/Cyt  women. Our expanded
secondary analysis concluded warranted the same primary screen-
ing intervals as the primary analysis but indicated that switching
at an earlier age could further reduce lifetime costs while main-
taining a similar reduction in the risk of cancer. We also found
that it was rarely attractive to refer younger women with LSIL
directly to colposcopy.
To our knowledge, this is the first analysis to evaluate the cost-
effectiveness of alternate screening strategies to prevent cervical
cancer in Norway. We expand upon previous modelling studies,
which look at primary HPV DNA testing in developed countries
(Goldie et al, 2004, 2006; Sherlaw-Johnson and Philips, 2004; Kim
et al, 2005; Bidus et al, 2006; Kulasingam et al, 2006; Goldhaber-
Fiebert et al, 2008) to include new alternative triage strategies for
older women who are HPV-positive, but cytology-negative. There
is no consensus regarding how to optimally manage HPV-positive
results to avoid over referral and unwarranted stress for women
(Cuzick et al, 2006a) and the choice of management strategy for
HPVþ/Cyt  women may depend on other factors such as
colposcopy resource constraints and preference to minimise
false-positive results. The proposed management approach
attempts to minimise the potential excess burden on resources
and use a risk management strategy that identifies only the women
at increased risk (i.e., those with persistent HPV infection) who
have not developed dysplasia detectable by cytology. As we varied
follow-up intervals of 6 or 12 months and number of persistent
HPVþ/Cyt  results required to prompt colposcopy, while
holding all else constant, yielded relatively marginal changes to
cancer risk reduction; our analysis suggests that it is rarely
attractive to refer women to colposcopy after one additional
HPVþ/Cyt  result. We found that switching to primary HPV
DNA testing at age 31 dominated switching at age 34, one
screening episode earlier than suggested by the Norwegian
proposal. This is likely because the prevalence of high-risk HPV
does not substantially change from 31 to 34 years, allowing women
to capitalise on the additional benefit of HPV testing without the
system incurring excess costs from a large number of transient
infections. Determining the optimal switch age is inherently
dependent on the natural history of HPV in older women.
Our analysis has clear limitations, many of which have been
described previously (Goldhaber-Fiebert et al, 2007; Kim et al,
2007; Kim and Goldie, 2008). We chose to use a detailed simulation
model that accommodates complex screening strategies and
individual history at the expense of explicitly modelling herd
immunity. In sensitivity analysis, we tried to simulate the indirect
effects (herd immunity) that HPV vaccination may have on the
incidence HPV-16, HPV-18 among unvaccinated women. We also
chose not to include other HPV-related diseases. It would be
expected that by preventing additional non-cervical cancers, we
would see improved cost-effectiveness. We acknowledge the
benefit of including quality-adjusted life years; however, cervical
cancer health state utilities have not been published in Norway,
and we therefore elected to express our results as cost per YLS.
Cost per quality-adjusted life year ratios would likely yield more
Table 2 Cost-effectiveness results for the analysis including additional strategies
Screening
start age
Screening
frequency,
pre-switch
(years)
Primary
screening
test,
pre-switch
Screening
switch
age
Screening
frequency,
post-switch
(years)
Primary
screening
test,
post-switch
Wait
time for
rescreen
HPV+/Cyt-
(months)
No. of
additional
HPV+/Cyt-
results to
colposcopy Vaccine
Absolute
reduction in
cancer (%)
Total
cost per
woman ($)
a
Total
LE
a
ICER
($/YLS)
Unvaccinated women
— — None — — — — — No — 120 32.9276 —
25 3 Cytology
b None None None 6
c 1
c No 55.45 1001 32.9502 Dominated
25 3 Cytology
b 31 6 HPV 12 3 No 55.59 760 32.9500 29000
25 3 Cytology
b 31 5 HPV 12 3 No 58.82 822 32.9510 57000
25 3 Cytology
b 31 4 HPV 12 3 No 63.44 922 32.9524 76000
25 3 Cytology
b 31 4 HPV 6 3 No 65.26 971 32.9529 98000
25 3 Cytology
d 31 4 HPV 6 3 No 65.39 982 32.9529 121000
25 3 Cytology
d 31 3 HPV 6 3 No 70.22 1160 32.9542 144000
25 3 Cytology
d 31 3 HPV 6 1 No 70.49 1200 32.9543 513000
Vaccinated women
— — None — — — — — No — 120 32.9276 —
— — None — — — — — Yes 63.54 646 32.9490 17000
25 3 Cytology
b None None None 6
c 1
c Yes 85.52 1541 32.9569 Dominated
25 3 Cytology
b 31 6 HPV 12 2 Yes 85.38 1267 32.9568 80000
25 3 Cytology
b 31 6 HPV 6 3 Yes 85.81 1279 32.9570 92000
25 3 Cytology
b 31 5 HPV 6 3 Yes 86.89 1339 32.9573 185000
25 3 Cytology
b 31 4 HPV 6 3 Yes 88.48 1439 32.9577 229000
25 3 Cytology
b 31 4 HPV 6 2 Yes 88.50 1442 32.9577 390000
25 3 Cytology
b 31 3 HPV 6 3 Yes 90.25 1609 32.9581 418000
25 3 Cytology
b 31 3 HPV 6 1 Yes 90.36 1625 32.9582 544000
25 3 Cytology
d 31 3 HPV 6 1 Yes 90.39 1636 32.9582 707000
Abbreviations: HPV¼human papillomavirus; LE¼discounted life expectancy; ICER¼incremental cost-effectiveness ratio; HPV+/Cyt : HPV-positive, cytology-negative result.
aDiscounted at 4% per year. All costs are expressed in 2010 US dollars (US$¼NOK6.05).
bCombo test triage (HPV/cytology) 6 months later for atypical squamous cells of
undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion results.
cHeld constant for all combo strategies for younger women.
dCombo test triage
(HPV/cytology) 6 months later for ASCUS results only.
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more conservative estimate.
Our cost estimates differed from those used for a previous
analysis assessing the cost-effectiveness of the HPV vaccination in
the context of the current screening programme in Norway
(Dasbach et al, 2008). There have been certain disease-specific
DRG updates (i.e., gynaecological brachytherapy; Norwegian
Directorate of Health, 2010) since the publication, which help
explain much of the difference in cancer treatment costs. The rank
ordering of the results were stable when we varied the cancer
treatment costs in our model from 50 to 200% of their base case
values. We have also chosen to include direct non-medical costs,
such as transportation and productivity loss directly attributable to
screening and treatment. Norwegian wages are among the highest
in the world and significantly contribute to the economic costs
associated with screening and treatment. Through sensitivity
analyses, we found that our main conclusion, with respect to
screening interval for vaccinated and unvaccinated women, were
robust to most cost assumptions; results were influenced only
when doubling the costs associated with the primary office visit.
One limitation of the proposed strategy, which requires repeated
follow-up of HPVþ/Cyt  women before colposcopy referral, is
the potential for loss-to-follow-up. Norwegian women are more
likely to ignore recommendations to follow-up equivocal and low-
grade results compared with those indicating a high-grade lesion
(Nygard et al, 2006). If the importance of continuing to follow-up
an HPVþ/Cyt  negative result is not communicated adequately
to women, the additional sensitivity of HPV testing could be
eroded. We did not evaluate whether this affects the optimal
strategy, but it should be considered as a potential drawback of
this particular screening algorithm.
The optimal strategies identified by this analysis will require a
comprehensive and dynamic system, which can alert women
according to their individual screening needs. More complex and
tailored screening algorithms will be more difficult to understand,
not only for women, but also for clinicians, who are responsible for
explaining and implementing strategies. Extensive monitoring of
the coverage, compliance, resource use, and outcome variables is
also crucial in order to allow the public health officials to identify
caveats and areas that are in need of improvement. Models can
never replace true-life evaluation and as data accumulate, our
model can be refined and revised.
CONCLUSION
Our objective was to provide quantitative insight to policy makers
about the trade-offs between different screening strategies, which
use new screening technology in the context of HPV vaccination.
We highlight the importance of alternative screening strategies
that are conditional on vaccination status and age. The optimal
strategies for vaccinated women determined by this analysis are
very similar to the strategy that has been proposed for pilot testing
in Norway (Cancer Registry of Norway, 2011). We shed light on the
potential benefits of switching to HPV DNA testing at an earlier
age and considering different screening recommendations for
those women who have not been vaccinated. Given a cost-
effectiveness threshold of $83000, it may be more efficient to
screen unvaccinated women, more frequently than those women
who were vaccinated during adolescents. We conclude that in
Norway, strategies involving a switch to primary HPV testing in
older women is expected to be cost-effective compared with the
current cytology-based screening programme.
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